natgillin/translations-raw huggingface dataset:
Another embodiment of the invention relates compounds of Formula (I) as defined above wherein n, Y and R1, R2, R6 are as defined above, R7 is hydrogen, R4 is hydrogen, the R3 in meta position is hydrogen and the R3 in ortho position is selected from the group consisting of halogen, preferably Cl or F, or C1-C4 alkyl, preferably methyl and R5 is an heterocyclic ring selected from pyrimidin-2-yl, pyridin-2-yl or pyrazin-2-yl, optionally substituted with halogen, preferably pyrimidin-2-yl optionally substituted with fluoro; 
Spoj formule (T) prema patentnim zahtjevima 1-4 naznačeno time da je R* vodik, R* u meta-položaju jest vodik a R? u ortho-položaju odabran je iz skupine koju čine halogen, ili C;-C, alkil, a R? je heterociklički prsten odabran od pirimidin-2-il, piridin-2-11l ili pirazin-2-1l, koji može biti supstituiran halogenom. Spoj formule (1) prema bilo kojem od prethodnih patentnih zahtjeva naznačeno time daje prsten A odabran iz skupine koju čine s s
In vitro release of the active ingredient was determined as in Example 1 and was: Released Time 
Oslobađanje in-vitro djelatne tvari iz pripravka je određeno kao u Primjeru 1 i iznosilo je:
FIG. 3 is a run diagram of a seasonal thermal energy storage system for heat supply and removal in summer according to one embodiment of the invention. 
Sustav sezonske pohrane toplinske energije za dovođenje rashladnog i toplinskog učina prema zahtjevu 2, naznačen time što korisnički terminal (5) je nisko temperaturna podna ploča za zračenje.
Step b): Providing a Ground Calcium Carbonate and/or a Precipitated Calcium Carbonate 
Hidrofobirani prirodni kalcijev karbonat i/ili hidrofobirani taložni kalcijev karbonat prema zahtjevu.
The exchange may also be performed by utilizing the low solubility of a desired salt. 
Izmjena se može također izvesti koristeći nisku topivost željene soli. u»
The designing process is a relief (4) formed by means of embossing on the inward facing surface of the filling layer (2). Relief (4) is the painting layer forming thickness and colour. 
Postupak kreiranja trodimenzionalne slike unutar transparentnog kamena (1) prema bilo kojem od predhodnih zahtjeva, naznačen time da navedeni drugi postupak dizajniranja je najmanje reljef (4) formiran na unutarnjoj površini navedenog sloja punjenja utiskivanjem.
After curing, first the extra foil layer and the sheetlike part are removed, after which the air-tight covering is removed. 
Nakon skrućivanja, prvi poseban sloj folije i dio sličan listu se odstrane, nakon čega se odstrani i neprodušan pokrov.
calculating (54) from said varying torque and said obtained rotational top end drive speed an estimated torque-speed transfer function; 
- izračunavanje (54) procijenjene funkcije prijenosa okretnog momenta u brzinu iz navedenog promjenjivog okretnog momenta i navedene dobivene vršne brzine vrtnje pogona;
Typically but not necessarily they would be arranged at equal angular spacings about the aforesaid pitch circle. 
Uobičajeno je, ali ne 1 neophodno, da mogu biti raspoređeni na jednakim kutnim razmacima oko već navedenog kruga.
An aqueous pharmaceutical preparation, which is a clear solution, comprising an active ingredient in a therapeutically effective and pharmacologically acceptable amount and alkoxylated fat, where the active ingredient is selected from the group consisting of roflumilast, salts of roflumilast, the N-oxide of the pyridine residue of roflumilast or salts thereof and poloxamer 188. 
PATENTNI ZAHTJEVI nasao Vodeni farmaceutski pripravak, naznačen time, da sadrži aktivni sastojak u terapeutski učinkovitoj i farmakološki prihvatljivoj količini te alkoksiliranu mast, pri čemu je aktivni sastojak izabran iz skupine koju čine roflumilast, soli roflumilasta, N-oksid piridinskog ostatka roflumilasta ili njegove soli.
is the linker L connected to the anti-DLL3 antibody M; 
R'" je poveznica spojena na protutijelo anti-DLL3;
The compounds of the invention are A2A receptors antagonists having a human A2A binding affinity (Ki) of 5 µM or less, typically of 1 µM or less, preferably of 550 nM or less, more preferred of 200 nM or less, even more preferred of 50 nM or less and most preferred of 10 nM or less. 
Spojevi ovog izuma su antagonisti A»,-receptora, koji imaju afinitet vezanja humanog A>2,-receptora (K;) od 5 uM ili manje, uobičajeno od 1 uM ili manje, preferirano 550 nM ili manje, više preferirano od 200 nM ili manje, i još više preferirano od 50 nM ili manje, te kao najviše preferirano od 10 nM ili manje.
The process according to claim 19, wherein the reaction temperature is in the range of 20 to 32°C. 
Postupak u skladu s patentnim zahtjevom 13, naznačen time što temperatura je u rasponu od 20 do 32 °C.
a serum half life which is elongated by factor 2 (more than 1.5) compared to an antibody which carries no detectable sialylation; 
(b) poluvijek u serumu koji je 2 puta dulji u usporedbi s protutijelom koje nije sijalilirano ili ima nizak stupanj opazivog sijaliliranje;
The apparatus according to claim 1, wherein the ignition means is integral with the blower. 
Uređaj sukladno bilo kojem od prethodnih patentnih zahtjeva, naznačen time, što je sredstvo za paljenje (34) integralno s puhaljkom (32).
Base addition salts included those salts that form with the carboxylate anion and include salts formed with organic and inorganic cations such as those chosen from the alkali and alkaline earth metals (for example, lithium, sodium, potassium, magnesium, barium and calcium), as well as the ammonium ion and substituted derivatives thereof (for example, dibenzylammonium, benzylammonium, 2-hydroxyethylammonium, and the like). 
Bazične adicijske soli uključuju one soli koje s karboksilatnim anionom tvore i uključuju soli dobivene s organskim i anorganskim kationima, poput onih koje se bira između alkalnih 1 zemnoalkalnim metalima (primjerice litijem, natrijem, kalijem, magnezijem, barijem i kalcijem), kao i amonijevog iona i njegovih supstituiranih derivata (primjerice dibenzilamonija, benzilamonija, 2-hidroksietilamonija).
A compound according to claim 1 wherein the compound is or a N-oxide, addition salt, quaternary amine, or metal complex thereof. 
Spoj prema zahtjevu 1, naznačen time da spoj je ili njegov N-oksid, adicijska sol, kvaterni amin ili metalni kompleks.
It is an object of the present invention to provide a beacon which is particularly resistant to external agents, in particular, steam, water, ice and snow. 
Cilj je predmetnog izuma da dade balizu koja je osobito otporna na vanjske čimbenike, osobito vodenu paru, vodu, led i snijeg.
The method of claim 16, wherein the at least one Yi which is identical to or differs with no more than one amino acid substitution from the contiguous stretch of amino acids naturally occurring in the protein to be detected is unique to said protein in said sample. 
Postupak u skladu s patentnim zahtjevom 16, naznačen time, da je barem jedan Y; koji je identičan ili se razlikuje od ne više od jedne aminokiselinske supstitucije iz susjednog proteina aminokiselina koje se prirodno pojavljuju u proteinima koji se detektiraju, jedinstven za navedeni protein u navedenom uzorku.
Flexible conduit according to a preceding claim, wherein the flexible body comprises a reinforcement layer (11) which extends with respect to the indentation for maintaining the form closed engagement of the flexible body and the at least one ring of the plurality of rings when the conduit is pressurized. 
Fleksibilni cjevovod sukladno prethodnom zahtjevu, pri čemu fleksibilno tijelo sadrži sloj ojačanja (11) koji se pruža u odnosu na udubljenje za održavanje zatvorenog oblika međudjelovanja fleksibilnog tijela 1 barem jednog prstena od više, u uvjetima pritiska u cjevovodu.
Use of a compound of Formula (I) according to any one of claims 1-10, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of an inflammatory disease, disorder or condition characterized by or associated with an undesirable inflammatory immune response, or an excessive secretion of TNF-a, IL-1, IL-6 and IL-8; or for the treatment of an inflammatory condition or immune or anaphylactic disorder associated with infiltration of leukocytes into inflamed tissue. 
Upotreba spoja Formule (I) u skladu s bilo kojim od patentnih zahtjeva 1-10, ili njegove farmaceutski prihvatljive soli, gdje je navedeni spoj namijenjen proizvodnji medikamenta za liječenje upalne bolesti, poremećaja ili stanja, naznačenih time što su ili su povezani s nepoželjnim upalnim imunosnim odgovorom ili prekomjernim lučenjem TNF-qa, IL-1, IL-6 i IL-8; ili za liječenje upalnog stanja ili imunosnog ili anafilaktičkog poremećaja povezanog s infiltracijom leukocita u upaljeno tkivo. .
a source of formamidine, such as formamidine (or a salt or derivative thereof, such as formamidine acetate, formamidine hydrohalide and/or formamidinesulfinic acid) or a mixture of an ammonium salt (e.g. 
(a) postupak se izvodi u prisutnosti formamidina, formamidin acetata, formamidin halogenvodika, formamidinsulfinske kiseline, ili smjese amonij klorida i mravlje kiseline; i/ili (b) I?
evaporating off a part of the solvent. 
isparavanje dijela otapala.
continuous cultivation of the cells. The method of claim 8, wherein the continuous cultivation of cells is: 
Postupak u skladu s patentnim zahtjevom 8, naznačen time što se kontinuirani uzgoj stanica:
ii) at least one border of a first color at least partially surrounding the at least one user marking area, 
Postupak prema zahtjevu 1, naznačen time da nadalje sadrži barem jednu oznaku unutar barem jedne korisnički označene ćelije.
A temperature of approximately 80 °C is well suited. 
Temperatura od 80*C je vrlo prikladna.
A kit for administering a composition, the kit comprising the pharmaceutical or cosmetic composition according any of the above claims and a dispenser. 
Komplet za primjenu pripravka, koji se sastoji od farmaceutskog ili kozmetičkog pripravka prema zahtjevu 1 ili 2 i dozatora.
the alkyl, alkenyl, and alkynyl portion of such substituents optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, halo, oxo, amino, alkyloxycarbonyl, alkylcarbonyloxy, hydroxy, alkyloxy, carbocyclyl, heterocyclyl, and cyano, wherein: the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl and alkyloxy, wherein: 
alkil, alkenil i alkinil dio takvog supstituenta po izboru je supstituiran jednim ili dva supstituenta neovisno odabranima iz skupine koja sadrži karboksi, halo, okso, amino, alkiloksikarbonil, alkilkarboniloksi, hidroksi, alkiloksi, karbociklil, heterociklil i cijano, gdje: amino je po izboru supstituiran jednim ili dva supstituenta neovisno odabranima iz skupine koja sadrži alkil i alkiloksi, gdje:
reacting the compound of formula (4), or salt thereof, wherein 
Postupak pripreme spoja sa formulom (1), ili njegove soli,
• means for detecting and adjusting the temperature in the treatment furnace, 
sredstva za otkrivanje i podešavanje temperature u peći za obradu, .
The system of claim 13, wherein the fourth software module configured to repair the invalid field, is configured to disable the invalid field. 
Sustav prema zahtjevu 9, naznačeno time da je četvrti softverski modul konfiguriran za popravak (106) nevažećeg polja konfiguriran za onemogućivanje (128) nevažećeg polja.
A method according to claim 14, wherein said inflammatory and/or obstructive airways disease is chronic obstructive pulmonary disease (COPD). 
Formulacija suhog praška prema patentnom zahtjevu 10, naznačeno time da upalna i/ili opstruktivna bolest dišnih puteva jest kronična opstruktivna plućna bolest (COPD).
adding lime to said deviated part of said second leach solution after said step of separating said precipitated aluminium hydroxide, causing precipitation of calcium carbonate; 
dodavanje (316) vapna u spomenuti izdvojeni dio spomenute druge otopine za ispiranje nakon spomenutog koraka razdvajanja spomenutog istaloženog aluminij hidroksida, čime se izaziva taloženje kalcij karbonata;
providing a compound of formula I' wherein X is Cl or Br, reacting the compound of formula I' with a compound of formula III to obtain a compound of formula IV' wherein X is as defined above, 
(i) - pripravljanje spoja formule I' f gdje X je Clili Br, (ii) reakcija spoja formule I' sa spojem formule III
More advantageous compounds of the invention have an EC50 value in this assay within the range of about 1 to about 10 µM. 
Povoljnije je kad spojevi izuma imaju ECs, vrijednost u tim ispitivanjima unutar raspona od oko 1-10 uM.
The fusion protein according to claim 1 wherein A is SEQ ID NO. 
Fuzijski protein u skladu s patentnim zahtjevom 1, naznačen time što ima SEQ ID NO.
The solid oral extended release pharmaceutical dosage form of claim 68, wherein the composition comprises at least about 80 % (by wt) polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000. 
Oralni farmaceutski oblik davanja s produljenim otpuštanjem u krutom stanju prema zahtjevu 1, naznačen time da sastav sadrži 10 mg oksikodon hidroklorida, i barem oko 85% (težine) polietilen oksida.
Use of a compound having the following Formula I or a salt thereof, in the manufacture of medicament for treatment of cancer. 
Loa 2 F Bo bo Ho ili njegove soli, u proizvodnji lijeka za liječenje raka.
nn. 005-C04-55-32-0 comprises a variable heavy chain domain corresponding to a nucleic acid sequence according to SEQ ID NO: 413, and an amino acid sequence according to SEQ ID NO: 225, and a variable light chain domain with a nucleic acid sequence according to SEQ ID NO: 485, and an amino acid sequence according to SEQ ID NO: 297, 
-H08-59-30-0 sadrži promjenjivu domenu teškog lanca koja odgovara sekvenci nukleinske kiseline u skladu sa SEQ ID NO: 349, te sekvencu nukleinske kiseline u skladu sa SEQ ID NO: 161, i promjenjivu domenu lakog lanca sa sekvencom nukleinske kiseline u skladu sa SEQ ID NO: 371, te sekvencu nukleinske kiseline u skladu sa SEQ ID NO: 183,
E represents CH; represents one —X—R4a substituent on the pyrrolidinyl ring (e.g. a substituent at the 3-position of the ring); 
(1) E predstavlja CH; (2) R' predstavlja supstituent -X-R* na 3-položaju pirolidinil prstena;
wherein the total non-volatile organic carbon content in the sodium nitrite is no greater than 2.5 ppm, or no greater than 10 ppm; wherein the sodium nitrite has total aerobic count of microbial load of no greater than 100 CFU/g, has total yeast and mold count of no greater than 20 CFU/g, contains no greater than 0.25 EU/mg of bacterial endotoxins; 
broj kvasca 1 plijesni nije veći od 20 CFU/g, ne sadrži više od 0,25 EU/mg bakterijskih endotoksina; pri čemu natrijev nitrit sadrži najmanje 97 tež% 1 ne više od 101 tež% natrijevog nitrita, mjereno USP kolormetrijskim testom; i pri čemu sadržaj teških metala u natrijevom nitritu nije veći od 10 ppm.
The clinker intermediate product is then tempered in a temperature range of 1200° C. up to a lower limit of 750° C., preferably in a temperature range of 1150 to 850° C., over a period of time sufficient to obtain the desired amount of C5S2$ as well as to convert a specific amount of aluminate and ferrate phases and residues of the crystalline high-temperature phases of the raw materials with remaining C$ into additional C4(AxF1-x)3$, where x is from 0.1 to 1, preferably from 0.95 to 0.8, and C5S2$. 
Postupak sukladno bilo kojem od zahtjeva 1 do 7, naznačen time što, uz C5925 i C4A,Fq.9)3$, klinker sadrži 0 do 30% po težini Cx(A,F(1.y)), s y opsega od 0.2 do 0.8, 0 do 20% po težini reaktivnih aluminata, 0 do 25% po težini periklasa (M), i O do 30% po težini sekundarne faze, relativno ukupnoj količini klinkera sa sadržajem sekundarne faze do 100%.
Untreated Number of Values 
Broj međunarodne objave:
Preparation of Benzylated Nebivolol Base (VIII) g of Isomer B (VII-B) and 14.70 g of A amine (Intermediate-I) were added to 50 ml of methanol and heated to 65-70° C. The reaction mass was maintained at the same temperature for 15 h. 
Dobivanje benzilirane nebivolol baze (VIII) 10 g izomera B (VII-B) i 14,70 g A amina (Intermedijer - I) dodano je u 50 ml metanola i zagrijano na 65-70 *C.
Compounds of general formula I wherein 
Spojevi s općom formulom I naznačeni time da
A method according to any one of claims 1 to 3, wherein the composition is administered by infusion or injection. 
Sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 6, pri čemu je sastav za davanje subjektu infuzijom ili injekcijom.
Optical Element An information system for displaying information, the system comprising: 
OPTIČKI ELEMENT ZA INFORMACIJSKI SISTEM ZA PRIKAZIVANJE INFORMACIJA
To summarise, as a main action the motor 12 drives the opening/closure movement of the extraction module. 
Ukratko, glavno djelovanje motora 12 je kretanje pri otvaranju/zatvaranju modula za ekstrakciju.
The compound according to claim 1 or 2, or a stereoisomeric form thereof, wherein R1 is phenyl optionally substituted with one or two substituents each independently selected from the group consisting of halo, C1-4alkyl, monohalo-C1-4alkyl, polyhalo-C1-4alkyl, -CN, -C1-4alkyl-O-C1-4alkyl, -O-C1-4alkyl, monohalo-C1-4alkyloxy and polyhalo-C1-4alkyloxy; 
Spoj prema zahtjevu 1 ili 2, ili njegov stereoizomerni oblik, naznačen time što je fenil po izboru supstituiran s jednim ili dva supstituenta od kojih je svaki neovisno odabran iz skupine koju čine halo, C1-4alkil, monohalo-C1-4alkil, polihalo-C1-4alkil, -CN, -C1-4alkil-O-C1-4alkil, -O-C1-4alkil, monohalo-C1-4alkiloksi i polihalo-C1-4alkiloksi;
The Compound of 23 according to Formula I(p): where R1, R2, R5, and R6 are hydrogen; X and R7 are halo; R10 and R12 are independently hydrogen, halo, or alkyl; R19 is hydrogen or alkyl; R3 is hydroxy; and R4 is heterocycloalkyl, alkyl, or heteroaryl, where the alkyl is optionally substituted with -NR8R8' and where the heteroaryl is optionally substituted with alkyl; or a single stereoisomer or mixture of stereoisomers thereof and optionally as a pharmaceutically acceptable salt or solvate thereof. 
[image] naznačen time što R1, R2, R5, i R6 su vodik; X i R7 su halogen; R10 i R12 su nezavisno vodik, halogen ili alkil; R19 je vodik ili alkil; R3 je hidroksi; i R4 je heterocikloalkil, alkil ili heteroaril, gdje je alkil po izboru supstituiran s -NR8R8' i gdje je heteroaril po izboru supstituiran s alkilom; ili pojedinačni stereoizomer tog spoja ili smjesa stereoizomera, ili po izboru njegova farmaceutski prihvatljiva sol ili solvat.
A method for differentiating normal fertile and sterile counterparts of an inbred line of a plant crop having a cytoplasmic or nuclear-cytoplasmic system of male sterility comprising the steps of: extracting chloroplastic DNA; 
Metoda za razlikovanje normalnih plodnih i sterilnih dijelova urođene linije biljnog usjeva koja ima citoplazmatski ili nuklearno-citoplazmatski sustav muške sterilnosti, naznačeno time da se sastoji od sljedećih koraka:
A package as claimed in any one of Claims 1 to 4, wherein the connecting tab (16) of the sealing flap (5) is glued to a flap (18) of the lid (7). 
Pakiranje u skladu sa bilo kojim patentnim zahtjevom 1 do 5, naznačeno time što je spojni jezičac (16) brtvenog kapka (5) zalijepljen na preklop (18) poklopca (7).
Method according to one of the claims 1 to 6, wherein the unit dosage form comprises the antibody or antigen-binding fragment thereof as liquid formulation, such as an injection or infusion solution. Method according to claim 7, wherein the liquid formulation is comprised in a hermetically sealed container, such as a vial, a sachette, a pre-filled syringe, a pre-filled autoinjector or a cartridge for a reusable syringe or applicator. 
Farmaceutski pripravak za uporabu u skladu s jednim od patentnih zahtjeva 1 do 11, naznačen time da oblik jediničnog doziranja sadrži protutijelo ili njegov fragment koji veže antigen kao tekuću formulaciju i u hermetički zatvorenoj posudi odabranoj iz skupine koju čine bočica, vrećica, prethodno napunjena štrcaljka, prethodno napunjeni autoinjektor, uložak za višekratnu štrcaljku, i aplikator.
In one embodiment, a combination consisting essentially of, or consisting of, the jB-lactamase inhibitor compound 1, or a pharmaceutically acceptable salt thereof, and sulbactam, or a pharmaceutically acceptable salt thereof, may optionally contain one or more pharmaceutically acceptable carriers, diluents and/or excipients, and optionally ampicillin or cefoperazone. 
Kombinacija za uporabu sukladno patentnom zahtjevu 4, nadalje sadrži jedan ili više farmaceutski prihvatljivih nosača, i/ili otapala, i izborno ampicilin ili cefoperazon. Kombinacija za uporabu sukladno patentnom zahtjevu 4 ili patentnom zahtjevu 5, naznačena time što je inhibitor B-laktamaze u obliku natrijeve soli.
The composition of the present invention comprises the ingredients in the following proportion. 
Pripravak ovog izuma obuhvaća sastojke u slijedećim omjerima.
The use of the system according to any of the claims 1-8, wherein the at least one penetration-promoting, anti-inflammatory agent of the second composition of the second component of the system constitutes 2 percent by weight of said second composition of the second component of the system. 
Upotreba sustava u skladu sa bilo kojim zahtjevom 1-8, naznačena time, što barem jedno sredstvo promicanja prodiranja, protu upalno, drugog sastava od druge komponente sustava predstavlja 2 posto po masi navedenog drugog sastava od druge komponente sustava.
wherein the basic amino acid or derivative thereof is selected from the group consisting of arginine, lysine, histidine, arginine-HCl, lysine-HCl, histidine-HCl, agmatine, L-arginine ethyl ester dihydrochloride, tranexamic acid, DL-5-hydroxylysine hydrochloride, L-lysine methyl ester dihydrochloride, 3-methyl-L-histidine, salts thereof and combinations thereof. 
pri čemu je bazna aminokiselina ili njezin derivat izabran iz grupe koja se sastoji od: arginina, lizina, histidina, arginina-HCl, lizina-HCl, histidina-HCl, agmatina, dihidroklorida etil estera L-arginina, traneksaminske kiseline, hidroklorida DL-5-hidroksilizina, dihidroklorida metil estera L-lizina, 3-metil-L-histidina, njihovih soli i njihovih kombinacija.
A composition comprising (a) a drug, agent, medication or hormone selected from the group consisting of levothyroxine, levothyroxine sodium, liothyronine sodium, liotrix, thyroxine and triiodothyronine and (b) a reduced folate, wherein the reduced folate is 6(S)-5-methyltetrahydrofolate. 
Pripravak koji sadrži (a) lijek, sredstvo, medikament ili hormon izabran iz skupine koju čine levotiroksin, levotiroksin natrij, liotironin natrij, liotriks, tiroksin i trijodtironin i (b) sniženi folat, gdje sniženi folat jest 6(S)-5-metiltetrahidrofolat.
Preferably said inhaler (5) is a plastic material with said strap and said body moulded as a unit. 
Poželjno, navedeni inhalator (5) načinjen je od plastičnog materijala pri čemu su navedena vrpca i navedeno tijelo izliveni kao jedan dio.
A method for preparing a vaccine composition, comprising preparing an emulsion according to any one of claims 1 to 8 and combining the emulsion with an antigen. 
Postupak pripreme sastava cjepiva koji sadrži pripremu emulzije prema bilo kojem od zahtjeva 1 do 18 1 kombiniranje emulzije sa antigenom.
wherein said patient maintains a DRL corresponding to consumption >60 g/day of pure alcohol for men and >40 g/day for women after an observation period following initial assessment, assessed by calculating mean daily alcohol consumption in g/day over said observation period; 
gdje navedeni pacijent održava DRL koji odgovara potrošnji >60 g dnevno čistog alkohola za muškarce i >40 g dnevno za žene nakon perioda praćenja koji slijedi za početnom procjenom;
The composition as claimed in claim 1, wherein a dosage unit comprises 300-1000 mg of gamma-linolenic acid. 
Sastav prema bilo kojem od patentnih zahtjeva od 11 do 14, naznačen time, da sadrži 300 do 1000 mg gama-linolenske kiseline.
The process according to claim 1, wherein, during step c), the halo compound used is other than dibromine. 
Postupak prema zahtjevu 1, naznačen time da je halogeni spoj korišten tijekom koraka c) različit od dibroma.